Aquestive Therapeutics, Inc. (NASDAQ:AQST) will hold its 3Q20 earnings conference call with the financial community on 5th November 2020 at 8:00 AM Eastern Time.
The company announced the financial results for the quarter on Wednesday 4th November 2020
The conference call will be webcast live on Internet at www.aquestive.com
Earnings Expectation
Aquestive Therapeutics, Inc. is expected to report third quarter earnings results, after market close, on Wednesday 4th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.46 per share from revenue of $ 8.72 million. Looking ahead, the full year loss are expected at $ 1.5 per share on the revenues of $ 47.32 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 35.00 million ~ $ 45.00 million
Click Here For More Historical Outlooks Of Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis.
